Earendil Labs vs Xaira Therapeutics
Side-by-side comparison of AI visibility scores, market position, and capabilities
Full-stack AI biologics company raised $787M in Mar 2026 backed by Sanofi, Pfizer/Hillhouse, and DST Global; $2.56B Sanofi collaboration signed Jan 2026; platform generates 40+ AI-designed protein therapeutics across multiple therapeutic areas.
About
Earendil Labs is a full-stack AI biologics company that uses a proprietary AI platform to design protein therapeutics at scale. The company secured $787 million in financing in March 2026, backed by Sanofi, the Pfizer-Hillhouse Biotech Fund, Dimension Capital, and DST Global — one of the largest AI drug discovery raises in the industry's history.
AI drug discovery startup launched with $1B funding. Led by ex-Stanford president + Nobel laureate David Baker. Focus: inflammatory/immunological diseases. Founded 2024, South SF.
About
Xaira Therapeutics is an AI-powered drug discovery company launched from stealth in April 2024 with $1 billion in committed capital. Headquartered in South San Francisco, incubated by Arch Venture Partners and Foresite Capital. Led by CEO Marc Tessier-Lavigne (ex-Stanford president, ex-Genentech CSO) and co-founder David Baker (Nobel laureate, UW Institute for Protein Design).
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.